US Bancorp DE lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 9.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 26,579 shares of the pharmaceutical company's stock after purchasing an additional 2,273 shares during the period. US Bancorp DE's holdings in Vertex Pharmaceuticals were worth $12,361,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in VRTX. Capital World Investors increased its position in Vertex Pharmaceuticals by 17.2% in the 1st quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company's stock valued at $10,687,339,000 after acquiring an additional 3,761,414 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Vertex Pharmaceuticals by 1.8% in the first quarter. Vanguard Group Inc. now owns 22,676,518 shares of the pharmaceutical company's stock valued at $9,479,011,000 after purchasing an additional 394,338 shares in the last quarter. Capital Research Global Investors raised its position in Vertex Pharmaceuticals by 61.0% in the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company's stock worth $2,401,000,000 after purchasing an additional 2,176,218 shares during the last quarter. Jennison Associates LLC lifted its holdings in Vertex Pharmaceuticals by 21.2% during the 1st quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company's stock worth $1,999,080,000 after buying an additional 837,461 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Vertex Pharmaceuticals by 10.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,584,315 shares of the pharmaceutical company's stock valued at $1,080,296,000 after buying an additional 244,336 shares during the period. 90.96% of the stock is currently owned by institutional investors and hedge funds.
Shares of VRTX stock opened at $471.12 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $341.90 and a 12 month high of $510.64. The company's fifty day simple moving average is $474.53 and its 200-day simple moving average is $464.95. The firm has a market cap of $121.60 billion, a PE ratio of -232.08 and a beta of 0.39. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The business had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The company's quarterly revenue was up 6.1% compared to the same quarter last year. During the same period last year, the firm earned $3.53 earnings per share. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -2.04 EPS for the current fiscal year.
Several equities analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $600.00 price target on shares of Vertex Pharmaceuticals in a report on Monday, October 21st. Royal Bank of Canada lowered their price target on shares of Vertex Pharmaceuticals from $431.00 to $425.00 and set a "sector perform" rating for the company in a research report on Friday, October 4th. UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Scotiabank assumed coverage on shares of Vertex Pharmaceuticals in a report on Wednesday, October 16th. They set a "sector perform" rating and a $480.00 target price for the company. Finally, Oppenheimer cut their price target on Vertex Pharmaceuticals from $550.00 to $540.00 and set an "outperform" rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $492.50.
Read Our Latest Stock Report on VRTX
In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the transaction, the director now directly owns 4,435 shares in the company, valued at $2,217,500. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Sangeeta N. Bhatia sold 646 shares of the firm's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the transaction, the director now directly owns 4,435 shares of the company's stock, valued at approximately $2,217,500. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the completion of the sale, the chief marketing officer now owns 23,259 shares of the company's stock, valued at approximately $11,088,728.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,710 shares of company stock worth $3,298,206. Corporate insiders own 0.20% of the company's stock.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.